Vandetanib Plus Pernetrexed Versus Pemetrexed as 2nd-Line Therapy in Patients with Advanced Nsclc: A Randomized, Double-Blind Phase Iii Trial ( Zeal)
Resource
JOURNAL OF THORACIC ONCOLOGY v.4 n.9 SUPPL. 1 pp.S356-S357
Journal
JOURNAL OF THORACIC ONCOLOGY
Journal Volume
v.4
Journal Issue
1
Pages
S356-S357
Date Issued
2009
Date
2009
Author(s)
YANG, CHIH-HSIN